TrianglePUBLICATIONS · 18235121
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2008 Feb 1
- First author
- Blanke CD
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Blanke CD
- type
- Author
- name
- Demetri GD
- type
- Author
- name
- von Mehren M
- type
- Author
- name
- Heinrich MC
- type
- Author
- name
- Eisenberg B
- type
- Author
- name
- Fletcher JA
- type
- Author
- name
- Corless CL
- type
- Author
- name
- Fletcher CD
- type
- Author
- name
- Roberts PJ
- type
- Author
- name
- Heinz D
- type
- Author
- name
- Wehre E
- type
- Author
- name
- Nikolova Z
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Blanke CD
- type
- Author
- name
- Demetri GD
- type
- Author
- name
- von Mehren M
- type
- Author
- name
- Heinrich MC
- type
- Author
- name
- Eisenberg B
- type
- Author
- name
- Fletcher JA
- type
- Author
- name
- Corless CL
- type
- Author
- name
- Fletcher CD
- type
- Author
- name
- Roberts PJ
- type
- Author
- name
- Heinz D
- type
- Author
- name
- Wehre E
- type
- Author
- name
- Nikolova Z
- type
- Author
- bibliography ids
- nci-bib-b9cda32c468a14a42f2ed9cc
- book metadata
- content sha256
- 93c3a35affdf2b4c4ed3e8e4002c935762047084171372ba74dd61bc303eef4c
- document type
- citation
- dois
- 10.1200/JCO.2007.13.4403
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:18235121
- immutable id
- pubmed:18235121@93c3a35affdf2b4c4ed3e8e4002c935762047084171372ba74dd61bc303eef4c
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 4
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 620-5
- volume
- 26
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 18235121
- provenance
- batch id
- e663b4be92ee60a9b059
- provider
- NCBI PubMed ESummary
- record sha256
- d40bd2912c5d8ec0a9d89b4755a1296ea4c6d767bb05972100ae4098c174400b
- response sha256
- 514286e846d1566a3f75c88a4af66b82adfc16ee2368b19bce657f2237aba90d
- retrieved at
- 2026-09-09T23:46:19.265979+00:00
- publication date
- display
- 2008 Feb 1
- precision
- day
- year
- 2008
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, U.S. Gov't, Non-P.H.S.
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Preserved source evidence · Not medical advice